Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Am J Transplant. 2019 Dec 27;20(4):977–987. doi: 10.1111/ajt.15739

FIGURE 6.

FIGURE 6

A, Diagram for in vivo skin graft experiments using blocking anti-TGF-β antibody. B, Representative skin graft sites at day 20 for anti-CD45RB treatment alone (upper panel) and anti-CD45RB+ anti-TGF-β (bottom panel). C, Control antibody (mIgG1, clone MOPC-21)–treated mice demonstrate long-term graft survival. Concurrent administration of neutralizing anti-TGFβ antibody with anti-CD45RB prevents the development of tolerance to OVA+ skin grafts in OBI mice. ns, nonsignificant. *P < .05. OBI, ovalbumin (OVA)-specific BCR mice; OVA, ovalbumin; TGF, transforming growth factor